VolitionRx Limited

(NYSE MKT:VNRX)

Latest On VolitionRx Limited (VNRX):

Date/Time Type Description Signal Details
2023-05-18 12:15 ESTNewsVolitionRx (VNRX) Presents At Inaugural Global Conference - SlideshowN/A
2023-05-12 02:01 ESTNewsVolitionRx Limited (VNRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-10 21:47 ESTNewsVolitionRX Q1 2023 Earnings PreviewN/A
2023-03-17 00:45 ESTNewsVolitionRx Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-17 00:45 ESTNewsVolitionRx Limited (VNRX) Q4 2022 Earnings Call TranscriptN/A
2023-02-17 08:52 ESTNewsVolitionRx slumps on pricing $7.5M in stock offeringN/A
2023-02-16 19:44 ESTNewsVolitionRx sinks 19% after hours on stock offering plansN/A
2022-11-16 02:48 ESTNewsVolitionRx Limited (VNRX) Q3 2022 Earnings Call TranscriptN/A
2022-11-15 09:31 ESTNewsVolitionRX reports Q3 resultsN/A
2022-11-14 00:21 ESTNewsVolitionRX Q3 2022 Earnings PreviewN/A
2022-10-20 23:22 ESTNewsVolition signs global supply agreement for NU.Q vet cancer testN/A
2022-08-13 19:04 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 01:06 ESTNewsVolitionRX Q2 2022 Earnings PreviewN/A
2022-08-11 01:06 ESTNewsVolitionRX reports Q2 resultsN/A
2022-08-08 10:29 ESTNewsVolition engages Diagnostic Oncology to conduct studies of Nu.Q cancer tests in USN/A
2022-08-03 12:18 ESTNewsVolitionRx secures $1.5M in non-dilutive fundingN/A
2022-08-02 22:22 ESTNewsXenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancerN/A
2022-07-29 19:51 ESTNewsVolitionRx stock slides on pricing $6M stock offeringN/A
2022-07-29 05:42 ESTNewsVolitionRx slides postmarket on public stock offeringN/A
2022-05-13 02:19 ESTNewsVolitionRx Limited 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-13 02:18 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 06:14 ESTNewsVolitionRX reports Q1 resultsN/A
2022-05-11 11:55 ESTNewsVolitionRX Q1 2022 Earnings PreviewN/A
2022-04-25 12:22 ESTNewsVolition launches Nu.Q Vet Cancer Test in Asia via distributorN/A
2022-03-31 20:50 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-31 01:39 ESTNewsVolitionRX reports FY resultsN/A
2022-03-29 14:22 ESTNewsVolitionRx stock rises 7% on license deal with Heska for Nu.Q Vet cancer screening testN/A
2022-01-21 02:35 ESTNewsVolition Nu.Q blood test combo detects colorectal cancerN/A
2021-12-20 16:23 ESTNewsVolitionRX: Cancer Diagnostic Tool For Our Best FriendsN/A
2021-11-13 05:56 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 17:53 ESTNewsVolitionRX EPS misses by $0.02, misses on revenueN/A
2021-09-25 11:49 ESTNewsVolitionRx files for $100M mixed shelf offeringN/A
2021-09-22 09:50 ESTNewsVolitionRx (VNRX) Investor Presentation - SlideshowN/A
2021-08-13 02:28 ESTNewsVolitionRx Limited 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-13 02:27 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-12 05:47 ESTNewsVolitionRX EPS beats by $0.02, misses on revenueN/A
2021-07-22 06:45 ESTNewsThe Prognosis For VolitionRxN/A
2021-03-30 14:35 ESTNewsVolitionRX (VNRX) Presents At Virtual Spring Investor Conference - SlideshowN/A
2021-03-24 08:04 ESTNewsVolitionRx Limited 2020 Q4 - Results - Earnings Call PresentationN/A
2021-03-24 08:04 ESTNewsVolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-23 12:10 ESTNewsVolitionRX EPS and revenue in-lineN/A
2021-03-17 10:58 ESTNewsVolitionRx stock up as data shows Nu.Q is effective in monitoring sepsisN/A
2021-02-18 12:35 ESTAnalyst RatingThe Analyst Target Price has increased from $7.66 to $8.Buy
2021-02-10 20:34 ESTNewsVolitionRx launches stock offeringN/A
2021-02-10 20:34 ESTNewsVolitonRx prices underwritten public offeringN/A
2021-01-30 18:40 ESTNewsStocks To Watch: Earnings Blaze In And More GameStop ManiaN/A
2021-01-26 12:53 ESTAnalyst RatingThe Analyst Target Price has increased from $7.16 to $7.66.Buy
2021-01-25 23:41 ESTNewsVolitionRx opens new manufacturing facility in Belgium, shares up 10%N/A
2021-01-06 12:06 ESTNewsVolitionRx granted additional $4M in non-dilutive fundingN/A
2021-01-01 13:03 ESTAnalyst RatingThe Analyst Target Price has increased from $7.13 to $7.16.Buy

About VolitionRx Limited (VNRX):

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.

VNRX Quotes by TradingView

See Advanced Chart

General

  • Name VolitionRx Limited
  • Symbol VNRX
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Full Time Employees 50
  • Fiscal Year EndDecember
  • IPO Date2007-04-25
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Supplies
  • Web URLhttp://www.volition.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 27491.32
  • Price/Book (Most Recent Quarter) 11.11
  • Enterprise Value Revenue 30648.48
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.11
  • Operating Margin -305935%
  • Return on Assets -48%
  • Return on Equity -102%
  • Revenue 6313
  • Earnings Per Share -$0.48
  • Revenue Per Share $0
  • Gross Profit 17096
  • Quarterly Earnings Growth -96.6%
View More

Highlights

  • Market Capitalization 200.49 million
  • EBITDA -16119203
  • PE Ratio -1.81
  • Analyst Target Price $8
  • Book Value Per Share $0.40
View More

Share Statistics

  • Shares Outstanding 52.73 million
  • Shares Float 32.07 million
  • % Held by Insiders 3708%
  • % Held by Institutions 14.39%
  • Shares Short 1.03 million
  • Shares Short Prior Month 1.21 million
  • Short Ratio 1.58
  • Short % of Float 3%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.83
  • 52 Week High $6.67
  • 52 Week Low $2.71
  • 50 Day Moving Average 4.6
  • 200 Day Moving Average 3.77
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

VolitionRx Limited (VNRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

VolitionRx Limited (VNRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$575-$0.09-$0.1119.64%
2020-06-302020-08-13$N/A-$0.12-$0.12-1.69%
2020-03-312020-05-07$N/A-$0.14-$0.10-44.78%
2019-12-312020-02-20$N/A-$0.08-$0.1127.27%
2019-09-302019-11-12$17096-$0.10-$0.116.28%
2019-06-302019-08-12$N/A-$0.11-$0.112.22%
2019-03-312019-05-08$N/A-$0.12-$0.12-4.35%
2018-12-312019-03-13$N/A-$0.11-$0.1418.52%
2018-09-302018-11-07$N/A-$0.14-$0.153.45%
2018-06-302018-08-13$N/A-$0.15-$0.151.64%
2018-03-312018-05-10$N/A-$0.17-$0.16-6.25%
2017-12-312018-03-01$N/A-$0.15-$0.164.76%
2017-09-302017-11-09$N/A-$0.15-$0.150%
2017-06-302017-08-09$N/A-$0.13-$0.147.14%
2017-03-312017-05-11$N/A-$0.13-$0.145.45%
2016-12-312017-03-10$N/A-$0.12-$0.1414.29%
2016-09-302016-11-10$N/A-$0.15-$0.13-13.21%
2016-06-302016-08-11$N/A-$0.13-$0.12-8.33%
2016-03-312016-05-13$N/A-$0.13-$0.147.14%
2015-12-312016-03-11$N/A-$0.14-$0.158.53%
2015-09-302015-11-04$N/A-$0.16-$0.13-23.08%
2015-06-302015-08-11$N/A-$0.10-$0.1428.57%
2015-03-312015-05-12$N/A-$0.12-$0.120%
2014-12-312015-03-18$N/A-$0.06
2014-09-302014-11-06$15000-$0.44
2014-06-302014-06-30$N/A$0.06
2014-03-312014-03-31$N/A-$0.18
2013-12-312013-12-31$N/A-$0.07
2013-09-302013-09-30$N/A-$0.08
2013-06-302013-06-30$N/A-$0.10
2013-03-312013-03-31$N/A-$0.09
2012-12-312012-12-31$27000-$0.16
2012-09-302012-09-30$28000-$0.09
2012-06-302012-06-30$11000-$0.10
2012-03-312012-03-31$16000-$0.09
2011-06-302011-08-31$N/A$-0.00
2011-03-312011-05-31$N/A$-0.00
2010-12-312011-02-28$-0.00
2010-09-302010-11-30$-0.00
2010-06-302010-08-31$-0.00
2010-03-312010-05-31$-0.00
2009-12-312010-02-28$-0.00
2009-09-302009-11-30$-0.00

VolitionRx Limited (VNRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

VolitionRx Limited (VNRX) Chart:

VolitionRx Limited (VNRX) News:

Below you will find a list of latest news for VolitionRx Limited (VNRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

VolitionRx Limited (VNRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.05CALL0 520FALSE00
2024-05-1750.05CALL0 220FALSE00
2024-05-177.50.05CALL0 190FALSE00
2024-05-172.51.7PUT0 1667.23TRUE00
2024-05-1750PUT0 0568.4TRUE00
2024-05-177.50PUT0 01408.04TRUE00
2024-06-212.50.1CALL0 10FALSE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.51.7PUT0 1512.43TRUE00
2024-06-2150PUT0 0612.17TRUE00
2024-06-217.50PUT0 0853.83TRUE00
2024-07-192.50.2CALL0 390193.16FALSE00
2024-07-1950.06CALL0 2080FALSE00
2024-07-197.50.03CALL0 1120FALSE00
2024-07-192.51.6PUT0 2379.05TRUE00
2024-07-1950PUT0 0299.87TRUE00
2024-07-197.56.54PUT0 0345.04TRUE00
2024-10-182.50.14CALL0 380142.08FALSE00
2024-10-1850.06CALL0 500FALSE00
2024-10-187.50CALL0 00FALSE00
2024-10-182.51.55PUT0 10TRUE00
2024-10-1850PUT0 0240.04TRUE00
2024-10-187.50PUT0 0222.86TRUE00

Latest VNRX Trades:

Date Shares Price
Jun 13, 2022 4:04 PM EST200$2.185
Jun 13, 2022 4:52 PM EST100$2.165

VolitionRx Limited (VNRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000466/0001078782-20-000466-index.htm
2020-02-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/93314/000000000020001370/0000000000-20-001370-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/93314/000107878219000829/0001078782-19-000829-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878219000892/0001078782-19-000892-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878219000924/0001078782-19-000924-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878219000925/0001078782-19-000925-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878219000926/0001078782-19-000926-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878219000927/0001078782-19-000927-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000012/0001078782-20-000012-index.htm
2020-02-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/93314/000107878220000086/0001078782-20-000086-index.htm
2020-02-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000087/0001078782-20-000087-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/93314/000107878220000100/0001078782-20-000100-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/93314/000107878220000104/0001078782-20-000104-index.htm
2020-02-18424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/93314/000107878220000120/0001078782-20-000120-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000133/0001078782-20-000133-index.htm
2020-02-2010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/93314/000107878220000134/0001078782-20-000134-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000141/0001078782-20-000141-index.htm
2020-04-01PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000230/0001078782-20-000230-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000233/0001078782-20-000233-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000261/0001078782-20-000261-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000262/0001078782-20-000262-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000263/0001078782-20-000263-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000264/0001078782-20-000264-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000265/0001078782-20-000265-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000266/0001078782-20-000266-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000267/0001078782-20-000267-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000268/0001078782-20-000268-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000269/0001078782-20-000269-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000270/0001078782-20-000270-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000271/0001078782-20-000271-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000280/0001078782-20-000280-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000296/0001078782-20-000296-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000305/0001078782-20-000305-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/93314/000107878220000306/0001078782-20-000306-index.htm
2020-05-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/93314/000107878220000357/0001078782-20-000357-index.htm
2020-05-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/93314/000107878220000361/0001078782-20-000361-index.htm
2020-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000366/0001078782-20-000366-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000367/0001078782-20-000367-index.htm
2020-06-17DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/93314/000107878220000447/0001078782-20-000447-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000466/0001078782-20-000466-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000558/0001078782-20-000558-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000559/0001078782-20-000559-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000560/0001078782-20-000560-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000565/0001078782-20-000565-index.htm
2020-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000595/0001078782-20-000595-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000610/0001078782-20-000610-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/93314/000107878220000621/0001078782-20-000621-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/93314/000107878220000623/0001078782-20-000623-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000635/0001078782-20-000635-index.htm
2020-08-194/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000657/0001078782-20-000657-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000658/0001078782-20-000658-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000687/0001078782-20-000687-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/93314/000107878220000704/0001078782-20-000704-index.htm
2020-05-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/93314/000121390020011325/0001213900-20-011325-index.htm
2020-06-02SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/93314/000121390020013959/0001213900-20-013959-index.htm
2020-06-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/93314/000121390020014581/0001213900-20-014581-index.htm
2020-06-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/93314/000121390020014608/0001213900-20-014608-index.htm
2020-07-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/93314/000121390020017036/0001213900-20-017036-index.htm
2020-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/93314/999999999520000376/9999999995-20-000376-index.htm

VolitionRx Limited (VNRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of VolitionRx Limited (VNRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3708%
Institutional Ownership: 1439%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-12-05Cameron John ReynoldsPresident and CEOBuy1,100.004.244,664.001,122,273.00https://www.sec.gov/Archives/edgar/data/93314/000107878219000892/0001078782-19-000892-index.htm
2020-05-22Cameron John ReynoldsPresident and CEOBuy4,000.002.7511,000.001,126,273.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000367/0001078782-20-000367-index.htm
2020-07-21Cameron John ReynoldsPresident and CEOBuy50,000.002.50125,000.001,176,273.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/0001078782-20-000560-index.htm
2020-07-21Cameron John ReynoldsPresident and CEOBuy50,000.003.00150,000.001,186,000.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/0001078782-20-000560-index.htm
2020-08-12Guy Archibald InnesDirectorBuy15,000.002.5037,500.001,369,975.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000635/0001078782-20-000635-index.htm
2020-08-12Guy Archibald InnesDirectorBuy15,000.003.0045,000.001,384,975.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000635/0001078782-20-000635-index.htm
2020-09-09Martin Charles FaulkesDirectorSell65,000.003.21208,650.001,505,943.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000687/0001078782-20-000687-index.htm
2020-08-10Micallef Jacob VincentChief Scientific OfficerBuy65,000.002.50162,500.00151,166.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000610/0001078782-20-000610-index.htm
2020-07-21Martin Charles FaulkesDirectorBuy30,000.002.5075,000.001,591,284.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000559/0001078782-20-000559-index.htm
2020-07-21Martin Charles FaulkesDirectorBuy30,000.003.0090,000.001,597,120.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000559/0001078782-20-000559-index.htm
2020-08-10Micallef Jacob VincentChief Scientific OfficerBuy65,000.003.00195,000.00161,008.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000610/0001078782-20-000610-index.htm
2020-08-17Michel GaetanInsiderBuy2,500.002.506,250.002,500.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000658/0001078782-20-000658-index.htm
2020-08-17Michel GaetanInsiderBuy2,500.003.007,500.003,214.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000658/0001078782-20-000658-index.htm
2020-09-15JASON BRADLEY MD TERRELLChief Medical OfficerSell19,500.003.2362,985.0034,949.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000704/0001078782-20-000704-index.htm
2020-04-13Edward FutcherDirectorBuy11,250.0038,250.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000268/0001078782-20-000268-index.htm
2020-07-21Rodney Gerard RootsaertSecretaryBuy30,000.002.5075,000.0039,828.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000558/0001078782-20-000558-index.htm
2020-07-21Rodney Gerard RootsaertSecretaryBuy30,000.003.0090,000.0046,214.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000558/0001078782-20-000558-index.htm
2020-01-12JASON BRADLEY MD TERRELLChief Medical OfficerSell11,364.004.7954,433.5650,000.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000012/0001078782-20-000012-index.htm
2020-09-18JASON BRADLEY MD TERRELLChief Medical OfficerBuy25,000.002.4761,750.0059,949.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000704/0001078782-20-000704-index.htm
2020-08-04JASON BRADLEY MD TERRELLChief Medical OfficerBuy12,500.002.5031,250.0062,500.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000595/0001078782-20-000595-index.htm
2020-08-04JASON BRADLEY MD TERRELLChief Medical OfficerBuy12,500.003.0037,500.0065,420.00https://www.sec.gov/Archives/edgar/data/93314/000107878220000595/0001078782-20-000595-index.htm